Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.70207 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Chloe Landy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Inflammation, Pulmonary Arterial Hypertension, Sex Characteristics, Hypertension, Pulmonary. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Heart Foundation of Australia, National Health and Medical Research Council, British Heart Foundation.
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a progressive and life‐threatening disease with limited treatment options. Sex differences are apparent in PAH, specifically in the pathophysiology, prognoses and pharmacological responses of patients. Inflammation and its resolution, which often differ between sexes, are dysregulated in chronic inflammatory conditions such as PAH. Inflammation is yet to be directly targeted by available PAH therapies despite its association with poor patient outcomes. Emerging research highlights the resolution of inflammation, an active process that restores tissue homeostasis, as a therapeutic avenue for treating chronic inflammatory diseases. This review encompasses the key pro‐resolving ligands and G protein‐coupled receptors involved in the active resolution of inflammation. We explore their dysregulation in PAH and evaluate their therapeutic potential, with a focus on how sex‐specific immune responses may influence both preclinical findings and clinical outcomes. Signalling pathways involved in the resolution of inflammation present many therapeutically relevant targets for the development of novel PAH therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
- Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
- School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
- Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Italy.
- Africa-Europe CoRE in Non-Communicable Diseases and Multimorbidity, African Research Universities Alliance (ARUA) and The Guild of European Research-intensive Universities, Glasgow, UK.
- Immunology Translational Research Programme, Department of Pharmacology, Yong Loo Lin School of Medicine, Singapore.
ORCID-Profile: Miles J De Blasio, Owen L Woodman, Pasquale Maffia, Hong Yong Peh, Cheng Xue Qin
Förderung
- National Heart Foundation of Australia
- National Health and Medical Research Council
- British Heart Foundation
Zitieren
APA
Landy, C., De Blasio, M. J., Woodman, O. L., Maffia, P., Peh, H. Y., & Qin, C. X. (2025). Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review. British Journal of Pharmacology. https://doi.org/10.1111/bph.70207
Vancouver
Landy C, De Blasio MJ, Woodman OL, Maffia P, Peh HY, Qin CX. Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review. British Journal of Pharmacology. 2025. doi:10.1111/bph.70207
BibTeX
@article{Landy2025,
author = {Landy, Chloe and De Blasio, Miles J and Woodman, Owen L and Maffia, Pasquale and Peh, Hong Yong and Qin, Cheng Xue},
title = {Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.70207}
}
EUVIMED